Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept

被引：35

作者：

Bagalas, V. ^{[1
]}

Kioumis, I. ^{[1
]}

Argyropoulou, P. ^{[1
]}

Patakas, D. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Dept Pulm Dis, Sch Med, G Papanikolaou Hosp, Thessaloniki 57010, Greece

来源：

CLINICAL RHEUMATOLOGY | 2007年 / 26卷 / 08期

关键词：

etanercept; rheumatoid arthritis; TNF-alpha antagonists; visceral leishmaniasis;

D O I：

10.1007/s10067-006-0356-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Visceral leishmaniasis (VL) is a severe disease that can develop in immunocompromised patients. Antitumor necrosis factor-alpha (TNF-alpha) treatment of rheumatoid arthritis can result in clinical benefits, but with an increased risk of opportunistic infections. Leishmania infection in patients treated with TNF-alpha antagonists is extremely rare; for this reason, we report a patient with VL after etanercept treatment who had an unfavorable outcome.

引用

页码：1344 / 1345

页数：2

共 10 条

[1] Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].